Amgen Knocks Roche In Early Round Of EPO Court Fight
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal judge rules that Roche’s EPO product Mircera infringes a key Amgen patent, although trial is still set for Sept. 4.
You may also be interested in...
Amgen EPO Patent Win Over Roche Could Derail Mircera Launch
Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.
Amgen EPO Patent Win Over Roche Could Derail Mircera Launch
Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.
Roche Hedges On U.S. Launch Of Mircera With November FDA Action Date Expected
Decision in Amgen’s patent infringement case against Roche over the continuous erythropoiesis receptor activator is expected in October.